Premium
Comparing the EQ‐5D‐5L crosswalks and value sets for England, the Netherlands and Spain: Exploring their impact on cost‐utility results
Author(s) -
Ben Ângela,
Finch Aureliano Paolo,
Dongen Johanna M.,
Wit Maartje,
Dijk Susan E.M.,
Snoek Frank J.,
Adriaanse Marcel C.,
Tulder Maurits W.,
Bosmans Judith E.
Publication year - 2020
Publication title -
health economics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.55
H-Index - 109
eISSN - 1099-1050
pISSN - 1057-9230
DOI - 10.1002/hec.4008
Subject(s) - schema crosswalk , eq 5d , bootstrapping (finance) , statistics , quality adjusted life year , cost–utility analysis , value (mathematics) , cost effectiveness , medicine , econometrics , mathematics , geography , health related quality of life , pedestrian , disease , archaeology , pathology
Abstract This study compares the five‐level EuroQol five‐dimension questionnaire (EQ‐5D‐5L) crosswalks and the 5L value sets for England, the Netherlands, and Spain and explores the implication of using one or the other for the results of cost–utility analyses. Data from two randomized controlled trials in depression and diabetes were used. Utility value distributions were compared, and mean differences in utility values between the EQ‐5D‐5L crosswalk and the 5L value set were described by country. Quality‐adjusted life years (QALYs) were calculated using the area‐under‐the‐curve method. Incremental cost‐effectiveness ratios (ICERs) were calculated, and uncertainty around ICERs was estimated using bootstrapping and graphically shown in cost‐effectiveness acceptability curves. For all countries investigated, utility value distributions differed between the EQ‐5D‐5L crosswalk and 5L value set. In both case studies, mean utility values were lower for the EQ‐5D‐5L crosswalk compared with the 5L value set in England and Spain, but higher in the Netherlands. However, these differences in utility values did not translate into relevant differences across utility estimation methods in incremental QALYs and the interventions' probability of cost‐effectiveness. Thus, our results suggest that EQ‐5D‐5L crosswalks and 5L value sets can be used interchangeably in patients affected by mild or moderate conditions. Further research is needed to establish whether these findings are generalizable to economic evaluations among severely ill patients.